<DOC>
	<DOC>NCT00702624</DOC>
	<brief_summary>The objective of this follow-up study is to evaluate whether corifollitropin alfa (Org 36286) treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) is safe for pregnant participants and their offspring.</brief_summary>
	<brief_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)</brief_title>
	<detailed_description>This is a follow-up protocol to prospectively monitor pregnancy, delivery, and neonatal outcome of women who were treated with corifollitropin alfa or recFSH and became pregnant during the base study P05690 (NCT00702845). For this trial no study specific assessments are required, but information as obtained in standard practice will be used.</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Participants who participated in base study P05690 (NCT00702845) and received at least one dose of either corifollitropin alfa (Org 36286) or recFSH in base study P05690; Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in base study P05690; Able and willing to give written informed consent.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neonatal outcome</keyword>
	<keyword>Congenital malformations</keyword>
	<keyword>In-Vitro fertilization</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Follow-up</keyword>
</DOC>